Here's what a successful negotiation with a government payer will get you: An 18% hike in your earnings forecast, about $150 million in additional sales, and a quick spike in share price. That's what Alexion yielded from a new reimbursement deal with France on its pricey rare disease treatment Soliris.
German medical device manufacturer Gerresheimer AG is expanding its presence in Georgia to take advantage of a boom in inhaler and insulin-pen demand. The investment is in the millions of dollars and will create additional 120 jobs in the process.
In 2010, Olympus bought Stryker's troubled OP-1 putty for $60 million, hoping to expand its market. Now, the Japanese maker of medical devices and cameras says it's selling the Lebanon, NH, plant where the putty is made at a bargain price--and if it can't make a deal it will close the facility.
Quintiles founder Dennis Gillings and a trio of private equity backers hauled in more than $400 million when the company first went public, and now they're looking to reap nearly $1 billion more in a secondary public offering.
After numerous setbacks and transitional moves, Columbia Laboratories has settled into its new identity as a CRO, closing its first full quarter of CRO revenue and plotting a brighter future.
Invuity's $36 million Series E debt and equity round announced last week will back a beefed up sales force, plus an expanded headquarters and manufacturing operation for its illumination technology and surgical tools. But is an IPO next? CEO Phil Sawyer isn't saying either way, choosing to remain mum about the San Francisco-based company's future financing plans.
Quotient, a U.K. focused on blood transfusion diagnostics, unveiled plans for an initial public offering that would raise as much as $75 million. The move continues a steady trickle of IPO movement among testing companies that began late last fall.
Vermillion's latest financial report yielded a mixed bag of results: Although the company reported a widening net loss due to increased spending for its research and product development, revenue grew for its software-based ovarian cancer diagnostic.
Biomet, a maker of medical devices based in Warsaw, IN, has reportedly filed with U.S. regulators for an IPO nominally valued at $100 million.
WuXi PharmaTech boosted its revenue 15.6% last year, and China's largest CRO is expecting to match that growth in the new year, counting on steady demand for manufacturing and a larger share of the U.S. research market.